Author Topic: (Abst.) Risk of SPMS: A longitudinal study  (Read 94 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9843
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Risk of SPMS: A longitudinal study
« on: August 11, 2019, 03:07:56 pm »

From PubMed (August 10, 2019)--"Risk of secondary progressive multiple sclerosis: A longitudinal study":

https://www.ncbi.nlm.nih.gov/pubmed/31397221


Though this study doesn't seem to be saying anything especially new, the last sentence in the abstract:


Quote
Therapy [with MS drugs] may delay the onset of secondary progression.


In the past there have been claims that therapy with MS drugs do delay the onset of secondary progression. This article states only that it "may delay" SPMS onset.



MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20 - 3/16/24.

Offline agate

  • Administrator
  • *****
  • Posts: 9843
  • MS diagnosed 1980
  • Location: Pacific Northwest
An editorial about this study--from Multiple Sclerosis Journal (August 12, 2019), "Big data in MS: What can we learn from large international observational studies such as MSBase?":


https://journals.sagepub.com/doi/full/10.1177/1352458519868982
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20 - 3/16/24.

 

Related Topics

  Subject / Started by Replies Last post
4 Replies
200 Views
Last post April 11, 2017, 07:11:54 pm
by agate
0 Replies
34 Views
Last post December 13, 2020, 09:50:14 pm
by agate
0 Replies
33 Views
Last post June 03, 2021, 08:37:51 pm
by agate
0 Replies
25 Views
Last post December 18, 2021, 08:51:29 pm
by agate
0 Replies
22 Views
Last post November 04, 2023, 10:04:01 pm
by agate